A comprehensive view of MiMedx Group Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
MiMedx Group enters an agreement with TELA Bio to gain exclusive rights to manufacturing and supply agreement with Regenity Biosciences; the deal allows MiMedx to add xenograft products to its portfolio of advanced wound care and surgical solutions
Published:
March 20, 2024
by GlobeNewswire
|
Ask us about our Tissue & Hygiene market view